Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says
Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020.
Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber Cancer Institute have released some much-needed good news. In their study, published in the journal Frontiers of Oncology on July 23, the researchers revealed that a chemical found in cannabis has demonstrated “significant therapy potential” in treatment of pancreatic cancer.
Stories you may be interested in
New Features
As Arfinn Med has become the leading Electronic Medical Record (EMR) and practice management solution for medical cannabis clinics, we have continued to release new features to help improve clinical workflows and patient care. Our newest feature is a custom intake form builder to help gather pertinent patient information prior to appointments. INTAKE FORM BUILDER…
Read More 
Cannabis reduces blood pressure in older adults, according to Ben-Gurion University researchers
Beer-Sheva, Israel…February 8, 2021 – A new discovery by researchers from Ben-Gurion University of the Negev (BGU) and its affiliated Soroka University Medical Center shows that medical cannabis may reduce blood pressure in older adults. The study, published in the European Journal of Internal Medicine, is the first of its kind to focus on the effect…
Read More 
Combating Opioid Dependence
The opioid epidemic is a hot topic across the United States, along with the alternatives that could alleviate the tragic consequences the epidemic brings. Opioids, also known as narcotics, are strong prescription pain relievers such as oxycodone, hydrocodone and fentanyl. Although illegal, heroin is also considered to be an opioid. Most patients are introduced to…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
Report of the Guideline Development Subcommittee of the American Academy of Neurology: We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More 
New approach to medical marijuana coming ‘very soon,’ DeSantis says
TALLAHASSEE — With one of his chief advisers tweeting the hashtag “NoSmokeIsAJoke,” Gov. Ron DeSantis said Monday he will “very soon” announce changes in how the state is carrying out a constitutional amendment that broadly legalized medical marijuana. Read the full story here.
Read More